CD19 molecule

Overview

CD19 is a transmembrane protein that plays a crucial role in the development and activation of B cells, a type of white blood cell integral to the immune response. It is primarily expressed on the surface of B cells and is involved in signaling pathways that regulate B cell proliferation, differentiation, and survival. Due to its restricted expression to B-lineage cells, CD19 has emerged as a prominent target for immunotherapy, particularly in the treatment of B-cell malignancies such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The development of chimeric antigen receptor (CAR) T-cell therapies targeting CD19 has revolutionized the treatment landscape for these diseases, providing new avenues for patients with refractory or relapsed conditions.

Focus of Latest Publications

Recent publications demonstrate CD19 as a continued central target for chimeric antigen receptor (CAR) T-cell immunotherapy across multiple B-cell malignancies and emerging solid tumor applications. Studies evaluated CD19-directed CAR-T therapies in relapsed or refractory B-cell acute lymphoblastic leukemia, non-Hodgkin's lymphoma, marginal zone lymphoma, multiple myeloma, and idiopathic multicentric Castleman disease, with several reports documenting complete responses and durable remissions. Beyond conventional approaches, investigations expanded into dual-targeting strategies (CD19/CD22 and CD19/CD20 combinations) to overcome antigen escape as a primary driver of treatment resistance, as well as allogeneic CD19-directed CAR natural killer (NK) cell therapy as a scalable alternative to autologous T-cell products.

Multiple strategies emerged to enhance CD19-targeted CAR-T potency and durability. Pharmacologic modifications during CAR-T manufacturing, particularly venetoclax treatment, augmented antitumor efficacy through non-apoptotic reprogramming of T-cell metabolism and signaling (IL-2/STAT5 and PI3K/AKT pathways). Computational design approaches optimized single-chain variable fragment (scFv) receptors to improve binding affinity across CD19 variants while minimizing predicted off-target interactions. A novel second-generation CAR construct utilizing a distinct CD19-binding epitope (HI19α) was evaluated as an alternative to commonly used FMC63-derived receptors, and combination strategies included supplementing interleukin-7 to enhance T-cell function when blinatumomab (a CD19-targeting bispecific engager) was paired with Src/BCR-ABL1 kinase inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia.

To extend CD19-directed therapy beyond hematologic malignancies, investigators developed innovative platforms including SHIFTERS, an ultrasound-triggered, hypoxia-gated system that induces local CD19 expression in solid tumors to activate nearby CAR-T cells, and CUTE (clickable universal tumor-antigen equipping), which used metabolic glycoengineering to artificially augment antigen density on tumor cells, stabilize CAR conformations, and reduce T-cell exhaustion.

Clinical outcomes were generally favorable, with complete or stringent complete responses and 100% minimal residual disease negativity reported in newly diagnosed multiple myeloma at six months, and sustained treatment-free remission documented in refractory Castleman disease beyond 12 months. However, complications requiring management included respiratory viral infections occurring in approximately 21% of CD19 CAR-T recipients over 18 months (predominantly SARS-CoV-2), and B-cell depletion-induced panhypogammaglobulinemia necessitating intravenous immunoglobulin replacement. These findings collectively support CD19 as a durable immunotherapeutic target while highlighting the importance of manufacturing optimization, receptor design refinement, and combination approaches to overcome resistance mechanisms and improve long-term efficacy.

Key Publications

• NEWJul Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight. (Hematological oncology, 2026, PMID 42339679): "she received 1×106 CAR+ T cells/kg of autologous CD19 CAR T cells on day 0."
• NEWJun Ultrasound priming gated by solid tumor hallmarks to guide CAR-T therapy. (Science advances, 2026, PMID 42268944): "...that rewires tumor hallmarks into the clinically validated antigen CD19 under focused-ultrasound (FUS) control."
• May Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort. (Journal for immunotherapy of cancer, 2026, PMID 42167809): "Dual-targeting CAR approaches recognizing CD19 and CD22 have shown promising clinical activity, but sustained remissions are limited by insufficient CAR T-cell persistence."
• May Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma. (Journal for immunotherapy of cancer, 2026, PMID 42144261): "Dual targeting of CD19 and CD20 may mitigate antigen loss."
• May Respiratory Viral Infections Following CD19 CAR T-Cell Therapy. (Journal of medical virology, 2026, PMID 42047272): "To describe the incidence, epidemiology, and clinical characteristics of RVI in patients who have received CD19 CAR T-cell therapy and identify independent risk factors for infection, we performed a retrospective, single-center cohort study including 101 patients treated with CD19 CAR T-cell therapy between April 2018 and January 2023."
• Apr Next-generation CD179a-CAR-T cells demonstrate potent and sustained anti-tumor activity in preclinical B-cell malignancies. (Molecular biology reports, 2026, PMID 42047877): "However, conventional CAR constructs targeting CD19 or CD20 often result in off-tumor toxicity due to shared antigen expression on healthy B-cells."
• Apr Therapeutic targeting of BCL-2 during CART cell production augments potency through non-apoptotic adaptive changes. (Signal transduction and targeted therapy, 2026, PMID 42036409): "Building upon this, we here investigate whether venetoclax-driven T cell reprogramming can be leveraged to enhance adoptive cell therapies, specifically using chimeric antigen receptor (CAR) T cells targeting CD19 as a model system."
• May Clickable Universal Tumor-Antigen Equipping Strategy for Remedial Chimeric Antigen Receptor T Cells to Destroy Solid Tumors. (ACS nano, 2026, PMID 42013422): "The CUTE strategy yielded a 5.7-fold higher antigen density than endogenous CD19 on Raji cells and markedly increased the functional avidity of CAR-T cells in vitro."
• Apr CAR-NK Cells in B-cell Lymphoma: A New Frontier toward Accessible and Scalable Cellular Therapy. (Blood cancer discovery, 2026, PMID 41996826): "In this phase II study, TAK-007, an off-the-shelf allogeneic CD19 CAR NK-cell therapy expressing IL-15, demonstrates encouraging response rates, rapid treatment availability, and an excellent safety profile in heavily pretreated B-cell lymphoma, including post-CAR-T patients, albeit with limited durability."
• Jun BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study. (Blood advances, 2026, PMID 41925575): "GC012F, now renamed AZD0120, is an autologous B-cell maturation antigen and CD19 dual-targeting chimeric antigen receptor (CAR) T-cell product manufactured on the FasTCAR platform."